Arne Claeys | Ruth Palmer Labhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/arne-claeys/Arne ClaeysHugo Blox Builder (https://hugoblox.com)en-ushttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/arne-claeys/avatar_hu1bffe4b6080593898e200da06093fd07_473044_270x270_fill_q75_lanczos_center.jpgArne Claeyshttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/arne-claeys/RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/ruvbl1_ruvbl2_neuroblastoma/Fri, 17 Apr 2026 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/ruvbl1_ruvbl2_neuroblastoma/Spatial transcriptomics exploration of the primary neuroblastoma microenvironment in archived FFPE samples unveils novel paracrine interactionshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/spatial_transcriptomics_neuroblastoma/Wed, 01 Oct 2025 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/spatial_transcriptomics_neuroblastoma/Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEANhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/clean/Thu, 11 Jan 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/clean/ATR inhibition enables complete tumour regression in ALK-driven NB mouse modelshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri1/Wed, 24 Nov 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri1/ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutationhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/Mon, 01 Feb 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/